PENDOPHARM to Promote Entocort® (budesonide) within Canada for Tillotts Pharma AGPrint
Agreement with Tillotts Pharma contributes to PENDOPHARM’s objective to lead the Canadian gastroenterological therapeutic field.
Montreal, Quebec (April 14, 2016) – PENDOPHARM, a division of Pharmascience Inc., today announced a promotional rights agreement with Tillotts Pharma AG (“Tillotts”) to provide marketing and detailing services for Entocort® (budesonide) to gastroenterologists in Canada. The agreement expands PENDOPHARM’s scope in specialty areas of the gastrointestinal (GI) market such as Inflammatory Bowel Disease (IBD), NASH and IBS-D.
Entocort is a locally-acting glucocorticosteroid, currently approved in more than 40 countries for the treatment of Crohn’s disease (CD) and, in some markets including Canada, ulcerative colitis (UC). CD and UC are types of IBD, one of the most prevalent GI diseases, affecting over 233,000 people in Canada.1 CD and UC are chronic, debilitating diseases that may lead to life-threatening complications. Symptoms vary, but often include abdominal pain and diarrhea. “We are pleased that Entocort will benefit from PENDOPHARM’s marketing expertise and existing strong network in the Canadian GI field.’’ said Mattias Norrman, Chief Operations Officer at Tillotts.
Hugo Boisvert, General Manager & Vice President, PENDOPHARM, said, “We are pleased to be working with Tillotts to promote Entocort’s therapeutic benefits to patients in Canada. Entocort is a strategic fit for our GI franchise and further develops PENDOPHARM’s presence in the GI field while adding a key product to our portfolio.”
Entocort is sold as capsules with enteric coated and delayed release pellets (for CD) and as enema (for UC).
Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with over 220 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products in the field of gastroenterology.
Tillotts successfully markets its own products Asacol™ (marketed in certain countries not including Canada), Entocort® and Colpermin®, as well as VistaPrep™ and in-licensed products, such as Simtomax®, in over 65 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world. For more information, visit the website www.tillotts.com.
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Entocort™, Entocir™, Entocord™, Budecol™ and Zentacort™ (transfer of registrations to Tillotts pending in certain countries). The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries (transfer of market authorisations to Tillotts in process) except for the USA.
PENDOPHARM is a division of Pharmascience Inc., a Canadian privately-owned company. Established in 1983, Pharmascience Inc. is the largest pharmaceutical company in Quebec, with a highly-skilled workforce of 1,600 people. It commercializes nearly 300 products, including branded prescription, OTC and BTC products as well as generic products in Canada with its affiliates and distributors in Europe, Asia, Middle East, Africa and Oceania.
Strategically committed to growth, PENDOPHARM is actively engaged in licensing, partnering, developing and marketing specialty prescription medicines as well as consumer brands.
For more information:
PENDOPHARM, Division of Pharmascience Inc.
Tel : (514) 340-9800 ext. 3055
1 Crohn’s and Colitis Foundation of Canada (CCFC). The impact of inflammatory bowel disease in Canada 2012 final report and recommendations. Available at: http://www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf Accessed: September 22, 2014